Autophagy modulation: a target for cancer treatment development (Q38271172)

1 September 2017

1 reference

title

Autophagy modulation: a target for cancer treatment development (English)

1 reference

1 September 2017

0 references

Alison Duffy

1

1 reference

1 September 2017

Jackson Le

series ordinal

2

1 reference

1 September 2017

Edward Sausville

series ordinal

3

1 reference

1 September 2017

Ashkan Emadi

series ordinal

4

1 reference

1 September 2017

publication date

25 November 2014

1 reference

Cancer Chemotherapy and Pharmacology

1 September 2017

published in

1 reference

1 September 2017

volume

75

1 reference

1 September 2017

issue

3

1 reference

1 September 2017

page(s)

439-447

1 reference

Autophagy: renovation of cells and tissues

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

The molecular machinery of autophagy: unanswered questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

The role of autophagy in cancer: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Regulation of macroautophagy by mTOR and Beclin 1 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Principles and current strategies for targeting autophagy for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

PI3K pathway alterations in cancer: variations on a theme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Autophagy modulation as a potential therapeutic target for diverse diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Removal of the BH4 domain from Bcl-2 protein triggers an autophagic process that impairs tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Autophagy modulation for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2637-Z

10.1007/S00280-014-2637-Z

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

1011715533

0 references

1 reference